Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815058 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT03815058 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 131 participants.
The verdict
NCT03815058, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL Autogene cevumeran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2025-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815058
The ClinicalTrials.gov registry entry for NCT03815058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03815058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815058 about?
NCT03815058 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.". This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
What is the current status of trial NCT03815058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2018-12-21. Estimated completion is 2025-01-21.
What interventions are being tested in trial NCT03815058?
The interventions under investigation include: Pembrolizumab (DRUG), Autogene cevumeran (BIOLOGICAL).
Who is sponsoring clinical trial NCT03815058?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.